Recruiting PHASE3 INTERVENTIONAL 3-arm NCT05397639

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Sponsor: Suven Life Sciences Limited

Conditions Agitation Alzheimer's Type Dementia

Interventions Masupirdine 100 mg Masupirdine 50 mg Placebo

Updated 12 times since 2022 Last updated: Jan 8, 2026 Started: Nov 1, 2022 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Agitation and Alzheimer's Type Dementia and is currently actively recruiting participants. Suven Life Sciences Limited leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3

▶ Show 7 earlier versions

Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Sep 2023 — Feb 2024 [monthly]

Recruiting PHASE3
Apr 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Apr 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suven Life Sciences Limited

Data source: Suven Life Sciences Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amherst, United States , Anaheim, United States , Beachwood, United States , Beaumont, United States , Belgrade, Serbia , Charleston, United States , Chicago, United States , Columbia, United States , Costa Mesa, United States , East Syracuse, United States and 21 more locations